Table 4.

Neutropenia, neuropathy, and pulmonary toxicity in North America

A+AVDABVD
Adverse event category, n (%)(n = 249)(n = 240)
Neutropeniaa
Incidence of neutropenia (any grade)154 (62)130 (54)
 Grade 3 or higher neutropenia146 (59)109 (45)
Incidence of febrile neutropeniab51 (20)22 (9)
Peripheral neuropathyc
Incidence of peripheral neuropathy (any grade)198 (80)134 (56)
 Grade 1 peripheral neuropathy102 (41)104 (43)
 Grade 2 peripheral neuropathy53 (21)28 (12)
 Grade 3 peripheral neuropathy43 (17)2 (<1)
Pulmonary toxicityd
Incidence of pulmonary toxicity (any grade)7 (3)25 (10)
 Grade 3 or higher pulmonary toxicity4 (2)14 (6)
  • aNeutropenia includes preferred terms of neutropenia and neutrophil count decreased.

  • bA total of 35 subjects received A+AVD and G-CSF primary prophylaxis. Of these, 3 subjects (9%) experienced febrile neutropenia.

  • cIncludes the preferred terms of peripheral motor neuropathy, peripheral sensorimotor neuropathy, peroneal nerve palsy, muscular weakness, hypotonia, or muscle atrophy.

  • dIncludes adverse events in the Interstitial lung disease Standardized MedDRA Query, MedDRA dictionary Version 19.0.